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Background: The molecular epidemiological studies showed that some variants of HPV-16, distributed geographically,
would present a higher risk of causing cervical cancer. This study aimed to analyze nucleotide changes of HPV-16 E6
and E7 genomic regions from infected Southwestern Congolese women.
Methods: DNA of twenty HPV-16 isolates was analyzed by amplifying the E6 and E7 genes using type-specific primers
PCR and direct sequencing. The sequences obtained were aligned with the HPV-16 GenBank reference sequences.
Results: Thirteen (65.0%) out of 20 DNA-samples were successfully amplified. Genetic analysis revealed 18 and 4
nucleotide changes in E6 and E7 genomic regions respectively. The most frequently observed nucleotide variations
were the missense C143G, G145T and C335T in E6 (100%), leading to the non-synonymous amino acid variation
Q14D and H78Y. E7 genomic region was found to be highly conserved with two most common T789C and T795G
(100%) silent variations. All HPV-16 variants identified belonged to the African lineage: 7 (53.8%) belonged to Af-1
lineage and 6 (46.1%) to Af-2 lineage. The missense mutation G622A (D21N) in the E7 region seems to be described
for the first time in this study.
Conclusion: This study reported for the first time the distribution of HPV-16 E6 and E7 genetic variants in infected
women from southwest Congo. The findings confirmed almost ascendancy of the African lineage in our study
population.
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The Republic of Congo has one of the highest rates
of cervical cancer incidence in Sub-Sahara Africa.
According to the World Health Organization (WHO),
the reported age-standardized incidence rate and age-
standardized mortality rate were 25.6 and 13.0 cases
per 100 000 women in 2014 [1].
Epidemiological and molecular studies are showed that
High-risk human papillomaviruses (HPV) types are the
etiological agents of cervical cancer [2,3]. HPV-16 is the* Correspondence: m.ennaji@yahoo.fr
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unless otherwise stated.most common high-risk genotype involved in cervical
cancer, representing for over 50% of all cases [4].
However, most HPV infections resolve spontaneously,
suggesting that other co-factors are necessary in the
persistence and lesion progression to cancer. These co-
factors include some variants of high-risk types such as
those of HPV16. Several molecular variants were de-
scribed and classified according to geographical regions
for the HPV-16 genotype [5,6]. Conventionally, a variant
is defined when there is a difference of less than 2% be-
tween the complete genomes of the same HPV type. A
difference from 1.0% has been used to define the lineage
and the sub-lineages variants by a difference from
0.5 to 1.0% between the lineages [7-9]. The variants
have been classified in six major phylogenetic lineages
(European, E; Asian, As; African-1, Af-1; African-2, Af-2;l. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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more than 98% nucleotide level similarity in L1 or E6
genes [10,11]. However, a new phylogenetic nomencla-
ture was proposed for the HPV-16 in four lineages as
follows: A (previously called European-Asian, EAS), B
(African 1, Af-1), C (African 2, Af-2), and D (North-
American/Asian-American, NA/AA) [7,9].
HPV-16 variants studies have shown that certain
intratypic-variants would contribute more than others to
the persistence of HPV infection and cervical cancer
progression [12,13]. In particular, non-European variants
are more highly oncogenic them European variants
[12,14,15]. Indeed, the importance of the E6 and E7
genes lies in their ability to transform and immortalize
the host cell. A single nucleotide change in these genes
could affect this ability, which would explain the differ-
ence in some variants to progress quickly them others to
cervical cancer [16]. E6 and E7 interacts with several
cellular proteins in particular, they inactivate the p53
and the pRb respectively, which are two cancer suppres-
sor major proteins [17].
In this perspective and with the advent of prophylactic
vaccines against HPV-16/18 and cervical cancer, it
becomes necessary to know the HPV genetic variants
present in each population.
In Congo, our previous study showed that the most
common genotype in invasive cervical cancer and its
precancerous lesions was HPV-16 [18]. Thus, to better
formulate immunization strategies and other preventive
measures in Congo, this preliminary study aimed to
analyze the nucleotide changes of the HPV-16 E6 and
E7 isolates in order to identify the different genetic
variants prevalent among infected women with cervical
carcinoma in southwest of the Congo.
Results
Out of 20 HPV-16 single infected cervical cancer sam-
ples examined in this study, the E6 and E7 genes were
able to be amplified and sequenced in 13 (13/20, 65.0%)
DNA samples. Nucleotide (nt) changes were analyzed
between nt 104 to 559 for E6 region and nt 562 to 858
for E7 region.
E6 nucleotide sequences analysis
By comparison with the HPV-16 reference sequence
(European prototype, NC_001526), mutation analysis
showed that 100% (13/13) of the analyzed sequences
contained at least one nucleotide change in the E6 re-
gion. Eighteen single nucleotide changes were observed
in HPV-16 E6 sequences, of which 13/18 (72.2%) were
non-synonymous mutations (all missense) and 5/18
(27.8%) were synonymous mutations (silent). The most
frequently observed variations were C143G (Q14D),
G145T (Q14D), T286A, A289G and C335T (H78Y), whichwas found in all samples. All nucleotide changes, variants
and their prevalence were reported in Table 1.
E7 nucleotide sequences analysis
The details of E7 mutations are summarized in Table 1.
E7 gene was found to be highly conserved in all cases
compared to E6 region. Only four single nucleotide
changes were observed in HPV-16 E7 sequences, with
2/4 (50.0%) missense and 2/4 (50.0%) silent. The most
frequently observed variations were the common silent
mutations T789C and T795G at codons 76 and 78,
which was found in all E7 sequences. However, the
common non-synonymous mutation A to G transition
at nt 647 and causing amino acid change N29S, was
found in 3 (23.0%) out of 13 sequences. An undescribed
mutation was found in three sequences in this study at
nt 622, that was generated a non-synonymous nucleo-
tide change G622A (D21N).
HPV-16 variants and phylogenetic analysis
All HPV-16 positive sequences analyzed belonged to the
African lineage, of which 7 (53.8%) out of 13 belonged
to Africain-1 lineage (Af-1) and 6 (46.1%) out of 13 to
Africain-2 lineage (Af-2). All African lines showed a
common pattern of five characteristic mutations in E6,
namely, C143G, G145T, T286A, A289G, and C335T,
which lead to two non-synonymous amino acid changes
Q14D and H78Y. In E7, all HPV-16 isolates showed a
common pattern of two silent mutations namely T789C
and T795G at codons 76 and 78 respectively. No Euro-
pean (E), Asian (As), Asian-American (AA) or northern
American (NA) lineages were detected in this study.
Phylogenetic trees were respectively built from eight
sequences E6 regions (Figure 1) and 5 of the E7 region
(Figure 2) from this study and other HPV-16 published
sequences available in GenBank.
Discussion
The HPV-16 genotype was recently identified as the
most prevalent genotype in cervical cancer cases and
high grade precancerous lesions in the southwest of
Congo [18].
To date, there are no molecular epidemiological stud-
ies on HPV-16 variants carried out in Congo. In the
present study, we characterized the nucleotide changes
of the HPV16 mono-infection isolates among infected
Congolese women with cervical cancer based on the E6
and E7 viral oncogenes analysis.
Several studies showed that HPV-16 variants may in-
fluence viral persistence and progression to cervical can-
cer, which partly explains the high prevalence of this
cancer in some populations compared to other [12].
Also, their distribution is geographically related and as-
sociated with the ethnic group [19,20]. The HPV 16 E6
Table 1 Nucleotide sequence variations of HPV-16 E6 and E7 genes, predicted amino-acid changes ant lineage classification in Southwest Congolese women
E6 nucleotide position E7 nucleotide position
Amino acid
changes
R10G R101/R10T L12I L12S P13G Q14D Q14H E29Q C51F A6IG D64E H78Y D2IN N29S
1 1 1 1 1 1 1 1 1 1 2 2 2 2 2 3 4 6 6 7 7
0 3 3 3 3 4 4 4 4 8 5 8 8 8 9 3 0 2 4 8 9
9 1 2 7 8 1 2 3 5 8 5 5 6 9 5 5 3 2 7 9 5
HPV16 Ref
(NC_001526)









Af-1 Af-la B1 4 (30.7) C g G T C a g T c g
Af-Ib/G295 B2 1 (7.7) C G T a g G T c g
Af-Ib/G131 B2 2 (15.4) G C G T a g T c g
Af-2 Af-2a/r C/C1 3 (23.0) c T G T a g T g A* c g
Af-2a/C109/
C138
1 (7.7) c T C G T a g G T g G c g
Af-2a/C109/
A137
1 (7.7) c T A G G T a g T g G c g
Af-2a/C109/
G285
1 (7.7) c T G T G a g T g G c g
Mutation
prevalence (%)
46.1 15.4 53.8/46.1 7.7 7.7 7.7 7.7 100 100 30.7 15.4 7.7 100 100 7.7 100 46.1 23.0 23.0 100 100














Figure 1 Maximum Likelihood Molecular Phylogenetic analysis using eight nucleotide sequences of HPV-16 E6 gene. Study sequences are labeled
in KP GenBank accession numbers. Others are reference GenBank sequences, including: NC_001526 (HPV-16 Ref), HQ644236, AF536179, HQ644238,
AF472508, HQ644237, AF472509, HQ644247, AF402678 and HQ644292. Phylogenetic trees were constructed by the Maximum Likelihood method and
the Kimura 3-Parameter model by MEGA package. Bootstrap proportions were calculated with 1000 replicates.
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genesis [21]. Any change in their sequences could induce
an alteration of the biological function of the proteins
encoded by these genes, which would justify the import-
ance of these kinds of studies, especially in the poorly
studied populations as ours.
In this study, phylogenetic analysis of HPV16 E6 and
E7 genes was performed to analyze the local distribution
of HPV16 lineages, according to the Yamada et al. [5]
classification. A total of eighteen point mutations in E6
and four in E7 genomic regions were found. Most
nucleotide changes reported in our study have been pre-
viously described. At least a nucleotide change was
observed in all sequences analyzed. This result is con-
sistent with the literature data indicating that more thanFigure 2 Maximum Likelihood Molecular Phylogenetic analysis using five n
in KP GenBank accession numbers. Others are reference GenBank sequences,
AF472508, HQ644237, AF472509, HQ644247, AF402678 and HQ644292. Phylog
the Kimura 3-Parameter model by MEGA package. Bootstrap proportions were90% of the E6 sequences contains mutations in cervical
carcinomas, whereas the E7 gene seems to be more con-
served [5,6,22,23].
At the E6 genomic region, five characteristic muta-
tions, C143G, G145T, T286A, A289G, and C335T defin-
ing the African lineage were found in our study as well
as it’s was previously described [8,11,24]. However, some
of the observed mutations are significant in the litera-
ture; in particular the two non-synonymous changes
African lineage located in E6 N-terminus coding region
at codon 10 and 14, which lead to amino acid changes
R10T and Q14D respectively. These amino acid changes
may lead to a difference in affinity with p53 and signifi-
cantly altered its degradation rate by this oncogene
[25,26]. Crook et al. [27] showed that the amino aciducleotide sequences of HPV-16 E7 gene. Study sequences are labeled
including: NC_001526 (HPV-16 Ref), HQ644236, AF536179, HQ644238,
enetic trees were constructed by the Maximum Likelihood method and
calculated with 1000 replicates.
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ity of E6 with p53. It is also reported that the amino acid
change R10I in addition to other mutations described
between nucleotide position 106 and 113 could lead to a
low affinity for binding of E6 and degrade p53 [25],
although these findings remain controversial and poorly
documented.
In contrast to E6, the E7 gene variability has been less
studied. Our studies on E7 showed a highly conserved
region of the HPV genome with some mutations (mainly
point mutations) described and few lead to amino acid
changes [23,28]. Out of four mutations identified in our
study, two were the common silent variations found in
all sequences. The two others were non-synonymous
mutations, of which a common described N29S was
found in three isolates (23%). This mutation often
described in Asia, was located in the cervical carcinoma
in Africa [23,29,30]. The importance of this amino acid
change was suggested by Zehbe et al. [22] because of its
location in an immunoreactive region. However, E7 pro-
tein with the N29S mutation present an identical power
transforming has the prototype strain, after measuring
the cooperation E7/activated ras gene in rat embryo
fibroblast cells [31]. In addition, N29S is involved in
binding to pRB and could alter the affinity of the E7 pro-
tein for pRB, or modification of the oncogenic potential.
But it was also proved that the variant A647G only binds
with similar affinity to that of the prototype [32,33]. The
D21N mutation (G622A) described in this study seems
to be for the first time. Only one case showed this
variation; future studies by sequencing after cloning in a
vector are needed to confirm its description in our
population.
All HPV-16 isolates examined in this study belonged
to the African lineage, of which 53.8% belonged to Af-1
lineage and 46.1% to Af-2 lineage. Our results are in
agreement with the literature. Indeed, the pioneering
studies of Yamada and Wheeler showed that the African
lineage was dominated in the continent. More than
90.7% of the variants in Africa region are African
lineage, of which 61% belongs to the Af-1 lineage and
29.7% to the Af-2 lineage [6,11].
Tu et al. [34] in South Africa, Qmichou et al. [35] in
Morocco and Buonaguro et al. [30] in Uganda reported
have identified in their respective studies 41%, 64.5%
and 100% of variants belonging to the African lineage.
These results substantially similar show the importance
of taking into account the African variants in the global
effort to fight against cervical cancer. The findings
obtained by Qmichou et al. [30] which reported 35.5%
of variants belonged to the Af-1 lineage and 29% to the
Af-2 lineage such as Yamada (61% Af-1 and 29.7% Af-2)
are consistent with ours by showing that the Af-1
lineage is predominant on the continent [11]. However,non-African lineages were also reported in the contin-
ent, especially in North Africa and South Africa regions.
The introduction of these lineages could be explained by
the diversity of their population with European popula-
tions. In our study, the absence of non-African lineages
could be explained by the small size of our sample, but
also by the fact that their frequency is very low in a
homogeneous African black population. However, fur-
ther investigation seems to be necessary to confirm this
hypothesis.
Knowing that HPV variants data are important in
developing HPV diagnostics, vaccines, and other thera-
peutic approaches to monitoring virus-induced diseases
[28], the major limitation of this study was the small size
of DNA-sample analyzed. However, this is the first study
that provides information on HPV-16 E6 and E7 genetic
diversity in Congolese women. A larger sample size of
HPV 16 including E6 and E7, but also L1 and LCR genes
will be necessary to better identify all the genomic
changes and appreciate their impact on the various
grades of cervical lesions.
Conclusion
The present study provides preliminary data on HPV16
E6 and E7 variants in the southwest of Congo. Findings
confirmed the predominance of the African lineage in
our samples, which could guide control strategies
against cervical cancer in Congo. However, future stud-
ies with a large sample are needed to better assess the
distribution of these variants depending on the grade
and the risk of developing cervical cancer.
Materials and methods
DNA Biological samples
DNA of twenty HPV-16 single infection isolates of
Congolese women with cervical cancer from our labora-
tory DNA bank (Laboratory of Virology, Microbiology
and Quality/ETB, Faculty of Sciences and Techniques de
Mohammedia, UH2C, Morocco) constituted from our
previous study [18] was investigated. In brief, All the
samples of biopsies were squamous cell carcinoma
(SCC) selected based on the availability of the DNA
sample. Samples were collected from the patients at-
tending the pathology laboratory of the General Hospital
of Loandjili (Pointe-Noire, Southwest Congo).
PCR amplification with type-specific (TS) primers and
sequencing
Amplification of HPV-16 E6 and E7 genes was per-
formed using TS primers flanking the encoding regions
of HPV16 E6 ORF (nt: 41–576) and HPV16 E7 ORF
(nt: 483–911), as previously described [36]. PCR was
performed with some minor modifications in 25 μL of
reaction mixture containing 1X PCR buffer, 2.5 mMMgCl2,
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primers, 0.025U/μl of Go Taq DNA polymerase (Promega)
and 1 μL of template DNA. The thermal program (Perkin
Elmer 2400 GeneAmp® PCR thermal Cycler, Scientific
Support, Inc, Hayward, CA) started with a pre-heat
of 94°C for 10 min, followed by 35 cycles according
to the protocol: 45 sec denaturation at 94°C, 45 sec
annealing at 49.5°C for E6 and 53.5°C for E7 and 45 sec
extension at 72°C, with 7 min final elongation at 72°C. For
each reaction, DNA from SiHa cell lines as positive con-
trols and Ultra-pure PCR water nuclease-free (Bioline, UK)
as negative PCR control were included.
PCR products were analyzed based on the expected
specific bands in 2% agarose gel. Type-specific PCR
products were directly sequenced using the “Big Dye
Terminator v3.1 Cycle Sequencing kit” (Applied Bio-
systems) according to the manufacturer’s instructions in
molecular and functional genomics platform (UATRS-
CNRST, Rabat, Morocco).
Phylogenetic analysis of sequences
The sequences were subsequently analyzed by NCBI
using online BLAST 2.0 software server (http://
www.ncbi.nih.gov/BLAST/) to confirm genotype and
amplified region. Multiple sequence alignments of the
full-length of E6 and E7 genes were performed using
BioEdit Sequence Alignment Software v7.0.4.1 and
Clustal W program [37]. HPV-16 DNA nucleotide posi-
tions were numbered according to the HPV-16 reference
(European prototype published in GenBank with accession
number: NC_001526.2) [38].
Phylogenetic trees were built by MEGA 5.1 package [39]
using a distance-based criterion, Tamura 3-parameter as
the substitution model [40] and Maximum Likelihood
algorithm with bootstrap proportions were calculated with
1000 replicates to test the robustness of the major phylo-
genetic groups [41]. The reference viral strains used for the
construction of phylogenetic trees were obtained from
the NCBI GenBank Database, which belong to Asian-
American lineage (GenBank accession numbers: AF402678;
HQ644247), African-1 (GenBank: AF472508; HQ644238),
African-2 (GenBank: AF472509; HQ644237) lineage, and
European lineage (GenBank: AF536179; HQ644236).
GenBank accession numbers
The representative nucleotide sequences from each region
sequenced in this study were deposited into GenBank
Database (http://www.ncbi.nlm.nih.gov/GenBank), under
the accession numbers KP313765 to KP313772 for E6 and
KP313773 to KP313777 for E7 genes.
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